title: Commentary on: "The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma." By Burzynski et al.
abstract: A potential effective therapy for diffuse intrinsic pontine glioma (DIPG) is far to be developed. There are no "shortcuts" to reach this goal. Only a rigid, scientific, and ethically correct approach can help develop effective therapeutic approaches for such a devastating brain tumor. There are no alternative ways. The children affected by DIPG deserve to become the focus of serious collaborative researches. For these children, there are many "lacks" which should be promptly corrected such as the lack of knowledge, the lack of basic and clinical scientists' passion to the problem of finding "the solution" for DIPG, the lack of rigid methods to run research in this frustrating field, the lack of research proposals, and the lack of serious, despite not magic, protocols to offer them.
authors.affiliation: Pediatric Clinical Division, University Hospital of Padua, Via Giustiniani 3, 35128, Padua, Italy, giorgio.perilongo@unipd.it.
authors.forename: Giorgio
authors.initials: G
authors.lastname: Perilongo
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D044482:Benzeneacetamides / Q000627:therapeutic use*; D020295:Brain Stem Neoplasms / Q000188:drug therapy*; D005260:Female; D005910:Glioma / Q000188:drug therapy*; D005973:Glutamine / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010648:Phenylacetates / Q000627:therapeutic use*; D010881:Piperidones / Q000627:therapeutic use*; D011149:Pons
chemical_list: D044482:Benzeneacetamides; D010648:Phenylacetates; D010881:Piperidones; D005973:Glutamine